Search - tctmd.com

Displaying 41 - 60 of 65

Sort: Relevancy | Date

Could Statins Curb Fatal or Severe COVID-19? Some Clues

News Daily News

Could Statins Curb Fatal or Severe COVID-19? Some Clues

Michael O'Riordan

August 14, 2020

Heart, Kidneys, Brain, and More: COVID-19’s Wide-ranging Effects

News Daily News

Heart, Kidneys, Brain, and More: COVID-19’s Wide-ranging Effects

Michael O'Riordan

July 13, 2020

Multiorgan Clotting in COVID-19 Hints at Platelets’ Role in Inflammatory Response

News Daily News

Multiorgan Clotting in COVID-19 Hints at Platelets’ Role in Inflammatory Response

June 25, 2020

Rivaroxaban May Yet Protect After a Hospital Stay: MARINER

News Daily News

Rivaroxaban May Yet Protect After a Hospital Stay: MARINER

June 25, 2020

Possible Antithrombotic and Anti-inflammatory Therapies for COVID-19

News Daily News

Possible Antithrombotic and Anti-inflammatory Therapies for COVID-19

Michael O'Riordan

June 08, 2020

Pulmonary Embolism in COVID-19 Patients: New Numbers, Little Consensus

News Daily News

Pulmonary Embolism in COVID-19 Patients: New Numbers, Little Consensus

Michael O'Riordan

April 29, 2020

How COVID-19 Promotes Thrombosis, Posing Problems for Drug-Drug Interactions

News Daily News

How COVID-19 Promotes Thrombosis, Posing Problems for Drug-Drug Interactions

Michael O'Riordan

April 22, 2020

New Questions About Triple Therapy After PAD Revascularization: VOYAGER PAD Substudy

News Conference News ACC 2020

New Questions About Triple Therapy After PAD Revascularization: VOYAGER PAD Substudy

April 02, 2020

Caravaggio Backs Apixaban for Prevention of VTE Recurrence in Cancer Patients

News Conference News ACC 2020

Caravaggio Backs Apixaban for Prevention of VTE Recurrence in Cancer Patients

April 01, 2020

Young MI Patients’ Ischemic Risk Extends at Least Two Decades

News Conference News ESC 2019

Young MI Patients’ Ischemic Risk Extends at Least Two Decades

September 06, 2019

FDA Approves Dalteparin Sodium as First Anticoagulant For Use in Pediatric VTE Patients

News Daily News

FDA Approves Dalteparin Sodium as First Anticoagulant For Use in Pediatric VTE Patients

Yael L. Maxwell

May 16, 2019

EXCEL Insights: CABG Outcomes for Left Main CAD Have Improved Substantially

News Daily News

EXCEL Insights: CABG Outcomes for Left Main CAD Have Improved Substantially

Michael O'Riordan

April 22, 2019

Final ANNEXA-4 Results Published, Confirm Rapid Andexanet Alfa Effects

News Conference News ISC 2019

Final ANNEXA-4 Results Published, Confirm Rapid Andexanet Alfa Effects

February 13, 2019

Top News in Endovascular Therapy: 2018

News Features

Top News in Endovascular Therapy: 2018

December 28, 2018

TCTMD’s Top 10 Most Popular Stories for October 2018

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for October 2018

October 31, 2018

TCTMD’s Top 10 Most Popular Stories for August 2018

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for August 2018

September 04, 2018

MARINER Fails to Meet Primary Endpoint Testing Rivaroxaban for Extended VTE Thromboprophylaxis

News Conference News ESC 2018

MARINER Fails to Meet Primary Endpoint Testing Rivaroxaban for Extended VTE Thromboprophylaxis

August 26, 2018

Intracranial Hemorrhage Outside of A-fib: Different NOACs, Different Risks

News Daily News

Intracranial Hemorrhage Outside of A-fib: Different NOACs, Different Risks

August 13, 2018

USPSTF Upholds Stance Against Hormone Therapy to Prevent Chronic Diseases in Menopausal Women

News Daily News

USPSTF Upholds Stance Against Hormone Therapy to Prevent Chronic Diseases in Menopausal Women

December 12, 2017

Low-Dose Rivaroxaban Plus Aspirin Lowers Some Costs in COMPASS, but Full Economic Impact Unclear

News Conference News AHA 2017

Low-Dose Rivaroxaban Plus Aspirin Lowers Some Costs in COMPASS, but Full Economic Impact Unclear

November 14, 2017

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.